Incannex Healthcare Limited
ASX:IHL.AX
Overview | Financials
Company Name | Incannex Healthcare Limited |
Symbol | IHL.AX |
Currency | AUD |
Price | 0.041 |
Market Cap | 65,067,410 |
Dividend Yield | 0% |
52-week-range | 0.041 - 0.28 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Joel Bradley Latham |
Website | https://www.incannex.com.au |
An error occurred while fetching data.
About Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD